Rationale: Idiopathic pulmonary fibrosis (IPF) is a chronic fatal lung disease with dismal prognosis and no cure. The potential role of the ubiquitously expressed SH2 domain-containing tyrosine phosphatase-2 (SHP2) as a therapeutic target has not been studied in IPF.
Objectives: To determine the expression, mechanistic role, and potential therapeutic usefulness of SHP2 in pulmonary fibrosis.
Methods: The effects of SHP2 overexpression and inhibition on fibroblast response to profibrotic stimuli were analyzed in vitro in primary human and mouse lung fibroblasts. In vivo therapeutic effects were assessed in the bleomycin model of lung fibrosis by SHP2-lentiviral administration and transgenic mice carrying a constitutively active SHP2 mutation.
Measurements and Main Results: SHP2 was down-regulated in lungs and lung fibroblasts obtained from patients with IPF. Immunolocalization studies revealed that SHP2 was absent within fibroblastic foci. Loss of SHP2 expression or activity was sufficient to induce fibroblast-to-myofibroblast differentiation in primary human lung fibroblasts. Overexpression of constitutively active SHP2 reduced the responsiveness of fibroblasts to profibrotic stimuli, including significant reductions in cell survival and myofibroblast differentiation. SHP2 effects were mediated through deactivation of fibrosis-relevant tyrosine kinase and serine/threonine kinase signaling pathways. Mice carrying the Noonan syndrome-associated gain-of-function SHP2 mutation (SHP2 D61G/1 ) were resistant to bleomycin-induced pulmonary fibrosis. Restoration of SHP2 levels in vivo through lentiviral delivery blunted bleomycin-induced pulmonary fibrosis.
Idiopathic pulmonary fibrosis (IPF) is a devastating chronic lung disease that leads to death within 3-3.5 years in nearly onehalf of patients (1, 2) . Current pathogenic theories suggest an aberrant woundhealing process in response to repetitive injuries to the alveolar epithelium in genetically predisposed individuals (3) (4) (5) (6) (7) . The IPF lung is characterized by extensive histological changes that include formation of fibroblast/myofibroblast foci, accumulation of extracellular matrix, and areas of aberrant remodeling interspersed with normal lung parenchyma (8) . Two drugs, pirfenidone (9) and nintedanib (10) , have been shown to slow lung function decline in IPF. Considering that nintedanib is a small-molecule tyrosine kinase inhibitor with activity against fibroblast growth factor receptor, vascular endothelial growth factor receptor, and plateletderived growth factor receptor (PDGFR), interest in aberrant tyrosine kinase activation in human lung fibrosis has been reinforced (11) .
The activation state of tyrosine kinases is usually tightly regulated by protein tyrosine phosphatases (PTPs) (12, 13) . The PTP family consists of receptor-like and nonreceptor proteins that affect signal transduction by removing phosphate groups from tyrosine residues of tyrosyl phosphorylated substrates. SH2 domain-containing tyrosine phosphatase-2 (SHP2), a ubiquitously expressed nonreceptor PTP containing two Src homology 2 (SH2) domains and one catalytic PTP domain, is encoded by the protein tyrosine phosphatase nonreceptor type 11 (PTPN11) gene (14) . Activating mutations in SHP2 underlie the Noonan syndrome that manifests as congenital heart disease, short stature, and facial dysmorphia (15, 16) . SHP2 regulates activated tyrosine kinase receptors including PDGFR, by binding to and dephosphorylating them (17, 18) . In mice targeted deletions of SHP2 in alveolar epithelial cells (AECs) (19) or macrophages (20) increase predisposition to fibrosis, but the expression of SHP2 in human pulmonary fibrosis or its potential therapeutic usefulness are still unknown.
When we analyzed SHP2 expression in IPF lungs we discovered that it was moderately expressed in hyperplastic alveolar and bronchiolar epithelium but generally not within areas of interstitial and peribronchial fibrosis. SHP2 inhibition promoted spontaneous fibroblast-tomyofibroblast differentiation in normal human lung fibroblasts (NHLFs), in vitro, and overexpression of SHP2 reduced the responsiveness of fibroblasts to profibrotic stimuli. SHP2 inhibition in vivo augmented bleomycin-induced pulmonary fibrosis, and restoration of SHP2 levels in vivo through lung-targeted lentiviral delivery or expression of a constitutively active mutant of SHP2 blunted bleomycininduced pulmonary fibrosis. Some of the results of these studies have been previously reported in the form of an abstract (21) .
Methods
For details, see the online supplement.
Gene Expression Data
We obtained gene expression data from the Lung Genomics Research Consortium (LGRC) gene expression data set (available at GSE47460 and the LGRC website [http://www.lung-genomics.org/], and described in We used empty pIRES-GFP plasmid (mock) and pIRES-GFP expression plasmids encoding wild-type SHP2, constitutively active E76A, and catalytically inactive R465M constructed as described (25, 26) . For the SHP2 knockdown experiment we used SHP2-specific small interfering RNA (siRNA) and nonspecific siRNA as control. Cells were treated with either transforming growth factor (TGF)-b1 (10 ng/ml), PDGF-BB (25 ng/ml), or phenylhydrazonopyrazolone sulfonate-1 (PHPS1) (5 or 10 mM). In most experiments we used commercially obtained NHLFs or primary mouse lung fibroblasts derived by us. For comparison between IPF and control lung fibroblasts we used primary fibroblasts obtained by C. Feghali-Bostwick (Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC) (27) .
Immunoprecipitation Phosphatase Assay
Briefly, SHP2 phosphatase activity assessment was performed by measuring released para-nitrophenyl phosphate (PNPP; New England BioLabs, Ipswich, MA).
Quantitative Real-Time PCR TaqMan (Life Technologies, Thermo Scientific Inc., Rockford, IL) was used according to the manufacturer's instructions, using b-glucuronidase as an internal control and manufacturer's specific primers and probes. Relative gene expression was normalized to a value of 1.0 for the unstimulated control group. Fold change was calculated by taking the mean of the controls as baseline.
Antibodies
A detailed list of antibodies is provided in the online supplement.
At a Glance Commentary
Scientific Knowledge on the Subject: Idiopathic pulmonary fibrosis (IPF) is a chronic fatal lung disease characterized by aberrant remodeling, accumulation of extracellular matrix, and formation of myofibroblast foci. The role of SH2 domain-containing tyrosine phosphatase-2 (SHP2), a ubiquitously expressed tyrosine phosphatase, has not been studied in IPF.
What This Study Adds to the Field: SHP2 is down-regulated in myofibroblast foci in IPF lungs. In cell culture, decreases in SHP2 induce profibrotic changes in lung fibroblasts, whereas enhanced expression of SHP reverses these changes. In an animal model of pulmonary fibrosis, lentiviral administration of SHP2 to the lung, or expression of a constitutively active SHP2 mutant, blunts fibrosis. Taken together, our results suggest that augmentation of SHP2 expression or activity should be investigated as a novel therapeutic strategy for IPF. Figure 1 . Decreased SH2 domain-containing phosphatase-2 (SHP2) expression in idiopathic pulmonary fibrosis (IPF) lungs and lung fibroblasts.
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(A) Analysis of the Lung Genomics Research Consortium cohort showed significantly decreased SHP2 expression in patients with IPF (n = 123) compared with control (CTRL) subjects (n = 96) (6.2 vs. 6.5, interquartile range [IQR], 6-6.5 vs. 6.3-6.8, respectively; *P , 0.0001; false discovery rate , 5%). Log 2 -transformed data are presented as box-and-whisker plots, with horizontal bars representing medians, top whisker representing maximal expression, and bottom whisker representing the fifth percentile. Mann-Whitney U test for independent samples. (B) Significant reduction in SHP2 mRNA levels
Lentivirus Production and Infection
Lentivirus production, 293T cell infection, and titer measurement were previously described (28) . ) mice are of mixed C57/BL6/SV129 background, so wild-type littermates were used as controls. All experiments used 9-to 12-week-old female C57BL/6 mice unless specified otherwise. Each experiment was performed twice by two independent researchers (A.T., G.Y.) blinded to the identity of the samples. Animals were blindly randomized to receive bleomycin, saline and PHPS1, or lenti-SHP2 or EV.
Assessment of Fibrosis
Histological analysis, immunohistochemistry, and the hydroxyproline assay are described in the online supplement.
Statistical Analysis
Data were statistically analyzed with MedCalc version 14 (MedCalc Software, Ostend, Belgium). We used the Mann-Whitney U test or an unpaired t test for comparisons between two groups and one-way analysis of variance for three or more groups. Data are presented as means 6 SD, and considered statistically significant at P , 0.05. Microarray statistical analysis was done, in which log 2 -transformed, cyclic loess-normalized (29) expression values of SHP2 were compared between IPF and control or chronic obstructive pulmonary disease (COPD) samples, using the Mann-Whitney U test for independent samples. A false discovery rate less than 5% was considered statistically significant.
Results

SHP2 Is Decreased in IPF Lungs
Analysis of LGRC gene expression data revealed that SHP2 was significantly decreased in IPF lungs (n = 123) compared with control lungs (n = 96) or COPD lungs (n = 123) ( Figure 1A ; and see Figure E1A and Table E1 in the online supplement).
LGRC microarray data were validated by qRT-PCR and immunoblot protein assays revealing statistically significant (P , 0.001), 3-and 2.5-fold decreases in SHP2 mRNA and protein ( Figure 1B; and Figures 1C and  1D, top) , respectively. Immunoblot analyses showed significantly decreased SHP2 expression in IPF lung fibroblasts compared with control lung fibroblasts ( Figures 1C and  1D , bottom). SHP2 showed moderate expression in the hyperplastic epithelium, was reduced mainly from areas of active fibroblastic foci ( Figure 1E , bottom), and did not colocalize with a-smooth muscle actin (a-SMA) in IPF lungs ( Figure 1F, bottom) . In control lungs SHP2 was expressed mainly by alveolar epithelial cells ( Figures 1E and 1F , and Figures E1B and E1C ).
Inhibition of SHP2 Expression or Catalytic Activity Promotes Fibroblast-to-Myofibroblast Differentiation
Transfection of NHLFs with siRNA reduced the expression of SHP2 mRNA and protein levels by 70% (Figures 2A and 2B) . Knockdown of SHP2 expression in NHLFs caused significant increases in a-SMA and collagen type I a1 (COL1A1) mRNAs (four-and fivefold, respectively) and protein levels (Figures 2A and 2B , and Figure E2A ) compared with controls. Immunofluorescence staining showed increased formation of stress fibers in si-SHP2-treated NHLFs compared with controls ( Figure 2C , and Figure E3A ), indicating differentiation of fibroblasts into myofibroblasts. To inhibit SHP2 catalytic activity, we treated NHLFs for 60 minutes with PHPS1, a cell-permeable phosphotyrosine mimetic that acts as a reversible, active site-targeting, substratecompetitive inhibitor of the catalytic domain of SHP2 (30) . Treatment of NHLFs with PHPS1 significantly increased the mRNA and protein levels of a-SMA and COL1A1 ( Figures 2D and 2E , and Figure  E2B ). Immunofluorescence revealed that SHP2 inhibition with PHPS1 caused the formation of stress fibers, characteristic of myofibroblast differentiation (31) , similar to those caused by TGF-b 1 ( Figure 2F , and Figure E3B ).
SHP2 Effects on Fibroblast Proliferation and Apoptosis
We performed gain-or loss-of-function experiments using wild-type SHP2, a constitutively active mutant (E76A), or a catalytically inactive mutant (R465M) in NHLFs. Wild type and E76A produced significant but moderate (1.2-fold) Figure 3A ). Both the wild-type SHP2 and E76A mutant caused significant increases in the mRNA and protein levels of caspase-3 and cleaved caspase-3 (c-CASP3), respectively (Figures 3B and 3C, and Figure  E2C ); however, they had only moderate effects on B-cell CLL/lymphoma 2 (BCL2) levels. SHP2-mediated fibroblast apoptosis was further confirmed by upregulation of caspase-3 and caspase-7 activity (6-fold) ( Figure 3D ) and increased numbers of TUNEL (terminal deoxynucleotidyltransferase dUTP nick end labeling)-positive cells (19- In line with previous reports showing dephosphorylation of PDGFR by SHP2 (32), both wild type and E76A reduced the PDGF-BB-induced phosphorylation of c-Abl (site 412), whereas R465M had no effect on PDGF-BB-induced activation of c-Abl ( Figure 5A , and Figure E2E 
SHP2 Inhibition Enhances Fibrotic Responses in the Bleomycin Model of Pulmonary Fibrosis
We investigated the effects of systemic inhibition of SHP2 catalytic activity, using PHPS1 given intraperitoneally (1.25 mg/kg) on Days 3 and 9 after bleomycin administration (Day 0). PHPS1 increased lung fibrosis both spontaneously and after bleomycin treatment, as indicated by significant increases in hydroxyproline levels (1.5-and 1.3-fold, respectively) and Masson's trichrome and a-SMA staining (Figures 6B and 6C), with no effect on SHP2 mRNA ( Figure 6A ).
Lentiviral Administration of SHP2 Attenuates Bleomycin-induced Lung Fibrosis
SHP2 expression was significantly decreased after bleomycin administration ( Figure  E5A ). We designed a lentiviral SHP2 expression vector to determine whether SHP2 overexpression will have an effect on pulmonary fibrosis. The wild-type SHP2 sequence was cloned into a lentiviral vector ( Figure E5B ) and mice were intratracheally infected with either SHP2-lentivector or EV 5 days before bleomycin or saline administration and killed on E6B ). Infection efficiency was confirmed by significant increases in SHP2 mRNA and protein levels (three-and twofold, respectively; P , 0.05) after SHP2-lentiviral administration compared with the EV-treated and saline-challenged animals ( Figures 7A-7C) . A significant threefold increase in SHP2 mRNA level was also noted in bleomycin-challenged mice treated with SHP2-lentivector compared with EV-treated animals. A trend toward an increase in SHP2 protein levels (threefold) after SHP2-lentiviral delivery, compared with EV-treated animals, was also observed in bleomycin-challenged animals; however, it did not reach statistical significance, a finding expected because only a small number of samples was available for protein analysis. Interestingly, SHP2 protein levels were inversely correlated to hydroxyproline levels (r = -0.68, P , 0.05; Figure E6C ), further supporting an association between reduction in lung SHP2 and increased experimental lung fibrosis. Immunohistochemical analysis suggested SHP2 overexpression in both the epithelial and stromal lung compartments in SHP2-treated animals compared with the EV-treated littermates ( Figure E6D ). Lentiviral restoration of SHP2 significantly blunted increases in hydroxyproline levels (1.35-fold) ( Figure 7D ); COL1A1, a-SMA, and fibronectin-1 (FN1) mRNAs (2.1-, 1.7-, and 2.2-fold, respectively) ( Figure 7E) ; but not COL3A1 expression levels (1.5-fold; not significant) ( Figure 7E ). Immunohistochemistry showed a substantial decrease in Masson's trichrome and a-SMA staining in mice treated with SHP2-lentivector compared with EV-treated mice ( Figure 7F , top and bottom, respectively).
The Noonan Syndrome-associated SHP2 Constitutively Active Mutant (SHP2 D61G/1 ) Confers Resistance to Bleomycin-induced Lung Fibrosis A mouse model bearing the Noonan syndrome common SHP2 gainof-function mutation (aspartate-toglycine substitution in amino acid 61; D61G), which renders the catalytic domain of SHP2 constitutively active, has been shown to faithfully recapitulate the human features of Noonan syndrome, but little is known of its lung phenotype (33) . We challenged heterozygous gain-offunction SHP2 mutants (SHP2 D61G/1 ) and wild-type littermates (SHP2 1/1 ) with bleomycin (3.0 U/kg) or normal saline. SHP2 D61G/1 mice were relatively resistant to bleomycin-induced lung fibrosis as indicated by significant reductions in hydroxyproline levels (1.4-fold) ( Figure 8A) ; mRNA levels of COL1A1 (2.9-fold), COL3A1 (3.3-fold), a-SMA (1.9-fold), and fibronectin (4.1-fold) ( Figure 8B) ; as well as Masson's trichrome and a-SMA staining ( Figure 8C , top and bottom, respectively). 
Discussion
Our study suggests a novel role for SHP2 down-regulation in pulmonary fibrosis through loss of its modulatory effects on fibroblasts. After the novel observation that SHP2 is preferentially decreased in IPF lung fibroblasts, we focused on the role of SHP2 in fibroblasts. We discovered that SHP2 catalytic activity was required to sustain steady state fibroblast differentiation and that reduction in the level or activity of SHP2 was sufficient to induce fibroblast-to-myofibroblast differentiation in primary human lung fibroblasts, as well as to increase their sensitivity to profibrotic stimuli. Overexpression of SHP2 or constitutively active mutants of SHP2 reduced the responsiveness of primary lung fibroblasts to profibrotic stimuli by dephosphorylation of major kinase-controlled profibrotic signaling pathways. Phenotypic analysis of primary lung fibroblasts obtained from mice heterozygous for the Noonan syndrome-associated SHP2 active mutant (SHP2 D61G/1 ) further confirmed the specific role of SHP2 in maintenance of fibroblast homeostasis. In vivo inhibition of SHP2 catalytic activity led to enhanced murine lung fibrosis, mice heterozygous for the Noonan syndrome-associated SHP2 active mutant (SHP2 D61G/1 ) were relatively resistant to bleomycin-induced lung fibrosis, and therapeutic lentiviral overexpression of SHP2 blunted bleomycin-induced pulmonary fibrosis, supporting a role for augmentation of SHP2 expression and activity as a therapeutic option in pulmonary fibrosis.
SHP2 is a ubiquitously expressed protein tyrosine phosphatase that plays a fundamental role in development and cell homeostasis (34, 35) . Global SHP2 deficiency is embryonically lethal in mice, due to major developmental defects (33, 36) . Support for a potential role for SHP2 in lung fibrosis has emerged from observations that targeted genetic ablations of SHP2 in AECs (19) or macrophages (20) are profibrotic. However, these studies did not assess the expression of SHP2 in human pulmonary fibrosis. When we analyzed tissues obtained from patients with IPF we discovered that SHP2 expression was preferentially decreased in myofibroblast foci. To study the consequences of SHP2 down-regulation in fibroblasts we employed transient gene knockdown, using siRNA, and catalytic domain inhibition, using PHPS1. Both SHP2 knockdown and SHP2 chemical inhibition caused spontaneous fibroblastto-myofibroblast differentiation as assessed by increased formation of stress fibers and up-regulation of fibrotic markers, suggesting that SHP2 expression and catalytic activity are required for maintenance of fibroblast differentiation. Our findings are consistent with earlier observations showing that fibroblasts lacking a functional SHP2 (37) or SHP2-knockdown mouse embryonic fibroblasts (17) exhibit increased formation of stress fibers. We complemented these observations by performing in vitro SHP2 gain-of-function experiments. Overexpression of both the wild-type SHP2 and an active mutant of SHP2 reduced their sensitivity to profibrotic stimuli and prevented TGFb 1 -induced fibroblast-to-myofibroblast differentiation. These in vitro results were augmented by in vivo observations that inhibition of SHP2 activity was profibrotic and that SHP2 augmentation blunted bleomycin-induced lung fibrosis. Taken together with the observations in the IPF lung, our results suggest a novel and critically important role for SHP2 activity in fine-tuning regulation of fibroblast phenotypes in pulmonary fibrosis.
The pathways by which SHP2 mediates its antifibrotic activity are of significant interest. We provide significant evidence that SHP2 affects both the PDGF-BB and TGF-b 1 pathways ( Figure  E7 ). Increased expression of SHP2 or of a constitutively active mutant of SHP2 was sufficient to sustain fibroblast homeostasis and blunted the response to profibrotic stimuli through attenuated PDGF-BBmediated c-Abl phosphorylation. This is in line with earlier in vitro data identifying endogenous Abl kinases as SHP2 substrates during PDFG-BB-mediated fibroblast proliferation (18) . Less clear is the observation that both transient expression of SHP2 and the Noonan syndrome-associated constitutively active mutant of SHP2 suppressed TGF-b 1 -mediated Smad2/3 phosphorylation. SHP2 is a tyrosine phosphatase and unlikely to directly dephosphorylate the serine/threonine site on Smad3. However, it has been shown that the nonreceptor tyrosine kinase c-Abl partly mediates the signaling events of the TGF-b 1 -induced serine/threonine kinase pathway (38) . Therefore, it can be speculated that the SHP2-induced deactivation of Smad2/3 could be the consequence of direct SHP2 phosphatase-dependent dephosphorylation of c-Abl. Our results are consistent with observations that SHP2 loss from AECs promotes epithelial-mesenchymal transition and fibrotic growth (19) but differ from those showing that SHP2 overexpression positively regulates TGFb 1 -induced airway remodeling in bronchial epithelial cells (39) . Although the reasons for this discrepancy are unclear, it is possible that SHP2 will have different effects on different cells as has been previously proposed (33) . More importantly, in the context of current U.S. Food and Drug Administrationapproved therapies, the emergence of SHP2 as a potential modulator of TGF-b 1 -and PDGF-BB-mediated fibrotic pathways, as well as our findings that expression of a constitutively active SHP2 mutant or lung-targeted lentiviral administration of SHP2 blunt pulmonary fibrosis, are of significant interest. It has been previously suggested that nintedanib is a phosphatase activator (32) and we observed that nintedanib restores PDGF-BB-mediated down-regulation of SHP2 expression and activity in NHLFs ( Figure E8 ). It is tempting to hypothesize that part of the effect of nintedanib is mediated through induction of SHP2, and thus it would be most effective in patients with low SHP2 activity. Our data exhibit a number of limitations. The present study was not designed to identify the causes for SHP2 deficiency in IPF lungs. Our in vitro and in vivo data suggest that SHP2 downregulation is induced by profibrotic stimuli (TGF-b 1 , PDGF-BB) or injury (bleomycin). Although the exact stimuli in the human lung are unknown, a role for the same profibrotic cytokines is suggested in human IPF, and it could be that these cytokines drive SHP2 downregulation in the IPF lung. However, it is possible that epigenetic modifications in the promoter region of SHP2, as happens in patients with leukemia (40), or effects of chronically enhanced changes in matrix stiffness, may affect SHP2 expression and could drive fibroblast-specific downregulation in humans. Similarly, the exact mechanisms underlying the therapeutic effects of SHP2-lentiviral restoration in the bleomycin model of lung fibrosis are still elusive. We hypothesize that SHP2 overexpression or inhibition promotes significant alterations in the phosphorylation states of several proteins involved in major signal transduction pathways. Because of the ubiquitous expression of SHP2 and its multitude of effects, it is possible that SHP2 inhibition may alter the general phosphorylation/dephosphorylation state of multiple signal transduction pathways in other cell types, not only fibroblasts, thus making the lung, as an organ, more susceptible to fibrosis, as has been previously described (19, 20) . This does not reduce the significant value of our observation that overexpression of catalytically active SHP2 has the potential to blunt fibrosis. However, it may suggest that additional experiments, including dissection of the contribution of SHP2 signaling in various cell types and detailed identification of all SHP2 targets, 
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will be required to decipher the therapeutic mechanism of SHP2 in lung fibrosis and allow us to discover additional cell-specific targets downstream of SHP2 signaling. In this context it is important to highlight that SHP2 augmentation is not without risk. In humans gain-offunction SHP2 mutations are associated with developmental disorders, the most well known being the Noonan syndrome (41) . Although most of the phenotypic aspects of the syndrome are associated with developmental defects induced by SHP2 activation during specific stages of embryonic and postnatal development, it seems logical to suggest that strategies aimed at activating SHP2 will be targeted to the lung. Like any other drug, detailed safety and efficacy studies will be required.
In conclusion, our present study reveals an important and previously unrecognized role of SHP2 as master regulator of fibroblast homeostasis and provides significant data to support its consideration as a therapeutic target in IPF. Loss of SHP2 expression and activity leads to enhanced fibrotic responses in both fibroblast cell lines and animal models of lung fibrosis. We provide significant evidence that restoring bleomycin-induced SHP2 down-regulation, using lentivirus in vivo, or genetically enhancing SHP2 activity, using a constitutively active mutant, attenuates fibrotic changes in a murine model of pulmonary fibrosis. Taken together with our observations that SHP2 is specifically down-regulated in myofibroblast foci in IPF, our results suggest that augmenting SHP2 activity should be evaluated as a novel and potentially effective antifibrotic therapy for patients with IPF. n Author disclosures are available with the text of this article at www.atsjournals.org.
